ImmuCell Corporation (ICCC)
| Market Cap | 75.88M |
| Revenue (ttm) | 15.23M |
| Net Income (ttm) | -1.52M |
| Shares Out | 7.21M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $10.52 |
| Previous Close | $10.64 |
| Change ($) | -0.12 |
| Change (%) | -1.13% |
| Day's Open | 10.73 |
| Day's Range | 10.39 - 11.80 |
| Day's Volume | 21,497 |
| 52-Week Range | 3.70 - 13.20 |
Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET
PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets sc...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2020 Results - Earnings Call Transcript
Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET
PORTLAND, Maine, Oct. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets sc...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2020 Results - Earnings Call Transcript
Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET
PORTLAND, Maine, July 07, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...
PORTLAND, Maine, June 16, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2020 Results - Earnings Call Transcript
PORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical pr...
PORTLAND, Maine, May 14, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (the “Company” or “ImmuCell”), a growing animal health company that develops, manufactures and markets s...
ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020
PORTLAND, Maine, April 02, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets...
PORTLAND, Maine, March 11, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2019 Results - Earnings Call Transcript
PORTLAND, Maine, Feb. 19, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...
ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019
PORTLAND, Maine, Jan. 21, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2019 Results - Earnings Call Transcript
PORTLAND, Maine, Sept. 17, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and marke...
PORTLAND, Maine, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and market...
Second Submission Anticipated Around Q3 2020
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2019 Results - Earnings Call Transcript
ImmuCell Corporation's (ICCC) CEO Michael Brigham on Q1 2019 Results - Earnings Call Transcript
About ICCC
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter o... [Read more...]
| Industry Biotechnology | IPO Date Apr 30, 1987 |
| CEO Michael Brigham | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol ICCC |
Financial Performance
In 2019, ImmuCell's revenue was $13.72 million, an increase of 24.91% compared to the previous year's $10.99 million. Losses were -$1.30 million, -44.20% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for ImmuCell stock is "Strong Buy" and the 12-month stock price forecast is 14.00.